MANILA, Philippines — More Filipino patients could eventually have opportunities to participate in international clinical research closer to home as pharmaceutical giant AstraZeneca Philippines teams up with AC Health to expand the country’s network of hospitals capable of conducting clinical trials.
The companies have signed a memorandum of understanding that will combine AstraZeneca’s clinical-research expertise with AC Health’s Healthway Medical Network, potentially developing more hospitals into qualified research sites outside the country’s traditional clinical-trial centers.
But the agreement comes with an important distinction: Healthway hospitals are not automatically becoming clinical-trial sites.
Participating facilities first have to demonstrate that they have the infrastructure, trained personnel, research systems and clinical capabilities needed to conduct trials safely and according to international standards. Individual studies will also remain subject to scientific, ethical, regulatory and feasibility reviews.
That could make the next phase of the partnership more significant than the signing itself.
Healthway hospitals to undergo trial-readiness assessments
Under the agreement, Healthway Medical Network will evaluate hospitals and other facilities in its network to determine which could potentially support clinical research.
The assessment is expected to look at infrastructure, clinical capabilities and institutional readiness while identifying doctors, investigators and other healthcare professionals who could participate in studies.
AstraZeneca, meanwhile, will provide technical expertise, training and assistance in preparing facilities for clinical research and accreditation, while potentially matching suitable sites with future studies.
The partnership has been described as AstraZeneca Philippines’ first clinical-research collaboration with an integrated hospital network, according to reports on the agreement.
That matters because Healthway’s footprint extends beyond Metro Manila into other parts of Luzon, the Visayas and Mindanao.
If facilities outside the capital eventually qualify for trials, researchers could potentially reach patients from a broader range of communities rather than concentrating studies in a limited number of major medical centers.
Why clinical-trial access matters
Clinical trials are one of the critical steps required before new medicines and treatment approaches can enter widespread clinical use.
They allow researchers to evaluate questions such as whether an investigational treatment is safe, how well it works, what dosage is appropriate and how its benefits and risks compare with existing treatments.
In the Philippines, clinical trials involving investigational products are regulated by the Food and Drug Administration.
The FDA’s current framework requires clinical trials to protect participants’ rights and safety while following internationally recognized Good Clinical Practice standards. It also gives regulators authority to review applications and monitor compliance through inspections.
That means participation in a trial should not be confused with receiving an already proven or approved treatment.
Investigational medicines may ultimately prove effective, ineffective or associated with previously unknown risks. Participants must therefore go through the appropriate eligibility and informed-consent processes before joining an approved study.
AstraZeneca says it already has more than 30 Philippine trials
The partnership also builds on AstraZeneca’s existing research presence in the country.
According to figures released by the pharmaceutical company and reported by several outlets, AstraZeneca currently has more than 30 ongoing clinical trials in the Philippines and says it has invested more than ₱3 billion in Philippine clinical research during the past six years.
The company’s local research activity spans major therapeutic areas including cancer, respiratory and immune-related diseases, and cardiovascular, renal and metabolic conditions, according to reports on the partnership.
AstraZeneca Philippines Country President Lotis Ramin said the collaboration could strengthen local research capabilities while expanding opportunities for patients and improving standards of care.
For AC Health, the agreement represents another step toward building capabilities beyond conventional hospital and outpatient services.
AC Health Chief Strategy and Investment Officer RJ Recio said the group wants its hospitals and physicians to be able to participate directly in clinical research rather than simply introduce new technologies and healthcare programs.
Healthway’s expanding footprint could be the real advantage
AC Health has been rapidly expanding its healthcare network.
Earlier this year, reports said the Ayala healthcare arm was pursuing further hospital acquisitions while growing its outpatient clinics and pharmacy operations. Its strategy includes expanding healthcare facilities into densely populated areas and major cities outside Metro Manila.
That geographic reach could prove particularly valuable in clinical research.
Large multinational studies often need enough qualified patients and investigators to generate reliable data. A wider hospital network potentially gives researchers access to more diverse populations while reducing the need for some patients to travel to Manila simply to participate in a study.
However, the availability of a Healthway facility in a particular city does not mean patients there will automatically become eligible for an AstraZeneca trial. A study must first be assigned to that facility, approved by regulators and ethics bodies, and opened to patients who satisfy its specific inclusion criteria.
AstraZeneca is also building ties with Philippine academe
The AC Health deal is not AstraZeneca’s only recent effort to expand the country’s healthcare research ecosystem.
In May, AstraZeneca Philippines signed another memorandum of understanding with De La Salle University centered on the university’s Knowledge, Innovation, Science and Technology Park in Laguna.
That partnership covers health research, talent development, internships, training and industry-academe collaboration and is intended to connect academic research with real-world healthcare applications.
Taken together, the DLSU and AC Health agreements suggest a broader strategy: develop research talent on one side while expanding the hospital infrastructure capable of conducting clinical research on the other.
The bigger question: When will patients actually see new trials?
For Filipino patients, the potential benefit is significant—but the timeline is still uncertain.
Neither AstraZeneca nor AC Health has publicly announced through the reports reviewed a definitive list of Healthway hospitals that have already been approved under this new partnership, the first specific studies that will be assigned to them, or when patient recruitment under the collaboration will begin.
And that may be the most important part of the story to watch.
The agreement creates the pathway. The next test will be whether hospitals across the Healthway network successfully meet the stringent requirements needed to become legitimate clinical-trial sites—and whether that ultimately translates into more research opportunities for Filipino patients outside the country’s traditional medical centers.
Leave a Reply